Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ovarian Neoplasms × Alendronate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Osteoporosis 5 Prostatic Neoplasms 3 Hypogonadism 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Genetic Diseases, Inborn 1

Interventions

Carboplatin 286 Paclitaxel 283 Bevacizumab 149 pembrolizumab 94 Gemcitabine 87 liposomal doxorubicin 86 Cyclophosphamide 83 Cisplatin 79 olaparib 77 Topotecan 77 niraparib 57 Docetaxel 51 Doxorubicin 46 Taxes 41 Drug Therapy 38 fludarabine 36 Nivolumab 34 Filgrastim 32 Specimen Handling 28 Etoposide 28 Magnetic Resonance Spectroscopy 26 durvalumab 23 Peripheral Blood Stem Cell Transplantation 23 Immunoglobulin G 23 Disulfides 23 Hyperthermic Intraperitoneal Chemotherapy 22 Albumin-Bound Paclitaxel 22 aldesleukin 20 Biopsy 20 atezolizumab 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00593580 2011-06-29

FOSAVANCE

British Columbia Cancer Agency

Phase 2 Completed

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡